Generic drug maker Sandoz must pay $26.34 million to Danish pharmacuetical giant Lundbeck and a subsidiary for infringing the Australian patent behind the blockbuster antidepressant Lexapro, a judge has found.
Drug maker Neurim Pharmaceuticals has won a bid to amend its Australian patent for top selling sleeping pill Circadin over the protests of two generic pharmaceutical companies, whch argued Neurim had purposely delayed the application to gain an unfair advantage in its infringement suit.
Pharmaceutical giant Allergan has streamlined its trade mark case against Self Care Corporation, which makes products marketed as Botox alternatives.
Canadian generic manufacturer Apotex has agreed to drop its lawsuit against India’s Cipla seeking to invalidate its Australian patent for popular nasal spray Dymista.
Motorola has accused rival Hytera Communications of a “deliberate strategy” of filing late affidavits to throw Motorola off in an already highly contentious patent and copyright case over digital radio devices.
US financial services giant State Street Global Advisers has brought legal action against Maurice Blackburn Lawyers, alleging the law firm’s plan to erect a copy of its Fearless Girl statue in Australia violates its trade mark and breaches consumer laws.
GM Holden has lost most of its case for design infringement against a company that imported and distributed spare car parts used to “up-spec” lower range Holden models, in the court’s first test of the Designs Act’s repair defence.
Mylan has appealed a ruling invaliding claims of its cholesterol drug patent and dismissing its patent infringement case against Sun Pharma.
A judge has panned evidence put on by Fuchs Lubricants in a patent dispute with Quaker Chemical as “woefully inadequate” and “absolutely garbage”, partially shooting down the firm’s attempt to block discovery of allegedly privileged documents.
Poppy processor TPI Enterprises has agreed to stop selling seed from high codeine poppy plants while it defends a lawsuit by rival Tasmanian Alkaloids alleging TPI infringed two of its innovation patents for high codeine-concentrated poppy.